Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

By E. Stein, C. Dinardo, D. Pollyea, A. Fathi, G. Roboz, J. Altman, R. Stone, D. DeAngelo, R. Levine, I. Flinn and 17 more. Blood, 2017

1,352 citations recorded by the source corpus.

Subfields: Hematology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/21a82c88940ef9fcaae3d7b1e59fb70775b4f239

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Public Health, Environmental and Occupational Health

1. Guido Kroemer
2. L. Galluzzi

Citations in the corpus

• Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML (2018, neutral): “Dose-escalation phase 4/33 (12) 5/35 (14) 12/78 (15)”
• Mitochondrial metabolism and cancer (2017, background): “That said, however, it should be noted that (1) RCD regulation at mitochondria involves a robust metabolic (rather than purely structural) component; (2) several metabolic aspects of the mitochondrial biology also influence therapeutic responses [101, 169] and (3) metabolic enzymes residing within m”
• Metabolic reprogramming and cancer progression (2020, background): “At least in AML, dependence on these mutant enzymes persists after the cancer becomes clinically apparent because mutant IDH inhibitors have therapeutic efficacy in humans (27).”